Influence factors and maintenance of peritoneal transport function in peritoneal dialysis patients

doi:10.3877/cma.j.issn.2095-3216.2014.03.010

Abstract

Abstract:

Peritoneal dialysis is an important replacement therapy for end-stage renal disease.Although the short-term technical survival of peritoneal dialysis is good, but ultrafiltration failure after longterm peritoneal dialysis is still the main cause for withdrawal of peritoneal dialysis treatment. The decline in peritoneal function can be attributed to its blood vessel proliferation and peritoneal fibrosis caused by glucose dialysate. However, the peritoneal function may also be affected by many other factors including diabetes,uremic toxins, drugs, peritonitis, and residual renal function. This review has been made regarding the related influencing factors and the possible intervention methods.

Key words: Peritoneal dialysis, Peritoneal transport function, Prognosis

Xueying Cao, Jianhui Zhou, Guangyan Cai, Xiangmei Chen. Influence factors and maintenance of peritoneal transport function in peritoneal dialysis patients[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(03): 160-165.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.03.010

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I03/160

References 78

1	Jain AK, Blake P, Cordy P, et al. Global trends in rates of peritoneal dialysis [J]. J Am Soc Nephrol, 2012, 23(3): 533-544.
2	Kamijo Y, Iida H, Saito K, et al. Normal peritoneum after nine years of peritoneal dialysis with biocompatible dialysate: a case report [J]. Perit Dial Int,2013,33(6):712-714.
3	Davies SJ, Phillips L, Griffiths AM, et al. What really happens to people on long-term peritoneal dialysis [J]? Kidney Int, 1998, 54(6):2207-2217.
4	Sampimon DE, Coester AM, Struijk DG, et al. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis [ J]. Nephrol Dial Transplant,2011,26(1):291-298.
5	Nakamoto H, Imai H, Kawanishi H, et al. Effect of diabetes on peritoneal function assessed by personal dialysis capacity test in patients undergoing CAPD [J]. Am J Kidney Dis, 2002, 40(5):1045-1054.
6	Mizumasa T, Hirakata H, Kuroki Y, et al. Diabetes influences peritoneal morphology in uremic patients at the initiation of peritoneal dialysis [J]. Perit dial Int,2013,33(2):175-181.
7	Honda K, Hamada C, Nakayama M, et al. Impact of uremia,diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology [J]. Clin J Am Soc Nephrol,2008,3(3):720-728.
8	Stoenoiu MS,De Vriese AS,Brouet A,et al. Experimental diabetes induces functional and structural changes in the peritoneum [J].Kidney Int,2002,62(2):668-678.
9	Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [J].N Engl J Med,2008,358(24):2560-2572.
10	Wang HY, Lin CY, Chien CC, et al. Impact of uremic environment on peritoneum: a proteomic view [J]. J Proteomics,2012,75(7):2053-2063.
11	Williams JD,Craig KJ,Topley N,et al. Morphologic changes in the peritoneal membrane of patients with renal disease [J]. J Am Soc Nephrol,2002,13(2):470-479.
12	Pletinck A, Consoli C, Van Landschoot M, et al. Salt intake induces epithelial-to-mesenchymal transition of the peritoneal membrane in rats [J]. Nephrol Dial Transplant, 2010, 25(5):1688-1696.
13	Shu KH, Chuang YW, Huang ST, et al. Association of interleukin-1beta gene polymorphism and peritonitis in uremic patients undergoing peritoneal dialysis [J]. Blood purification, 2011, 32(3):156-160.
14	Uchiyama K, Naito K, Tsuchida M, et al. Impact of a genetic polymorphism of the interleukin-1 receptor antagonist on technique survival in peritoneal dialysis patients [J]. Blood purification,2005,23(6):450-458.
15	Flessner MF, Credit K, Henderson K, et al. Peritoneal changes after exposure to sterile solutions by catheter [J]. J Am Soc Nephrol,2007,18(8):2294-2302.
16	Peters T, Potter R, Li X, et al. Mouse model of foreign body reaction that alters the submesothelium and transperitoneal transport[J]. Am J Physiol Renal Physiol,2011,300(1): F283-F289.
17	Chung SH, Heimburger O, Lindholm B. Poor outcomes for fast transporters on PD: the rise and fall of a clinical concern [J].Semin Dial,2008,21(1):7-10.
18	Yang X, Fang W, Bargman JM, et al. High peritoneal permeability is not associated with higher mortality or technique failure in patients on automated peritoneal dialysis [J]. Perit Dial Int,2008,28(1):82-92.
19	Oba I, Shinozaki M, Harada K, et al. Icodextrin-based continuous ambulatory peritoneal dialysis therapy effectively reduces left ventricular mass index and protects cardiac function in patients with end-stage renal disease [J]. Adv Perit Dial,2013,29:14-18.
20	Heaf JG. Peritoneal transport: getting more complicated [J].Nephrol Dial Transplant,2012,27(12):4248-4251.
21	Fernandez-Reyes MJ, Bajo MA, Del PG, et al. The influence of initial peritoneal transport characteristics, inflammation, and high glucose exposure on prognosis for peritoneal membrane function [J].Perit Dial Int,2012,32(6):636-644.
22	McDonald SP, Collins JF, Rumpsfeld M, et al. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations [J]. Perit Dial Int, 2004, 24(4):340-346.
23	Dejardin A, Robert A, Goffin E. Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PDrelated complications [J]. Nephrol Dial Transplant,2007,22(5):1437-1444.
24	Han SH, Lee SC, Ahn SV, et al. Improving outcome of CAPD:twenty-five years' experience in a single Korean center [J]. Perit Dial Int,2007,27(4):432-440.
25	Chow KM, Szeto CC, Cheung KK, et al. Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis[J]. Clin J Am Soc Nephrol,2006,1(4):768-773.
26	Ates K, Nergizoglu G, Keven K, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients [J]. Kidney Inter,2001,60(2):767-776.
27	Wang AY, Woo J, Wang M, et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function [J]. Nephrol Dial Transplant,2005,20(2):396-403.
28	Maiorca R, Brunori G, Zubani R, et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study [ J]. Nephrol Dial Transplant,1995,10(12):2295-2305.
29	Bargman JM, Thorpe KE, Churchill DN, et al. Bargman JM,Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study [J]. J Am Soc Nephrol,2001,12(10):2158-2162.
30	Han SH,Lee SC,Ahn SV,et al. Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients [J]. Nephrol Dial Transplant,2007,22(9):2653-2658.
31	Li PK, Chow KM, Wong TY, et al. Effects of an angiotensinconverting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study [J].Ann Intern Med,2003,139(2):105-112.
32	Suzuki H, Kanno Y, Sugahara S, et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD [J]. Am J Kidney Dis,2004,43(6):1056-1064.
33	Kolesnyk I, Dekker FW, Noordzij M, et al. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients [J]. Perit Dial Int,2007,27(4):446-453.
34	Li PK, Cheng YL. Therapeutic options for preservation of residual renal function in patients on peritoneal dialysis [J]. Perit Dial Int,2007,27(Suppl 2): S158-S163.
35	Johnson DW, Clarke M, Wilson V, et al. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function [J]. BMC nephrol,2010,11:25.
36	Johnson DW, Brown FG, Clarke M, et al. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial [J].Nephrol Dial Transplant,2012,27(12):4445-4453.
37	ter WPM, van Ittersum FJ. The new peritoneal dialysis solutions:friends only, or foes in part [J]? Nat Clin Pract Nephrol, 2007, 3(11):604-612.
38	Krediet RT. Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death [J]? Perit Dial Int,2013,33(6):715-718.
39	Kawanishi K, Honda K, Tsukada M, et al. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis [J].Perit Dial Int,2013,33(3):242-251.
40	Lee HY, Choi HY, Park HC, et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome [J]. Nephrol Dial Transplant,2006,21(10):2893-2899.
41	Cho Y, Johnson DW, Badve SV, et al. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients [J]. Kidney Int,2013,84(5):969-979.
42	Nessim SJ, Perl J, Bargman JM. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum [J]? Kidney Int,2010,78(1):23-28.
43	Mizuiri S, Ohashi Y, Hemmi H, et al. Effects of new peritoneal dialysis solutions, pyridoxamine and AT1 receptor blocker, on TGFbeta1 and VEGF expression in rat peritoneal mesothelial cells [J].Am J Nephrol,2009,30(3):295-302.
44	Duman S, Gunal AI,Sen S,et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution[J]? Perit Dial Int,2001,21(2):219-224.
45	Jing S,Kezhou Y,Hong Z,et al. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients [J]. Nephrology,2010,15(1):27-32.
46	Wontanatawatot W, Eiam-Ong S, Leelahavanichkul A, et al. An update on RAAS blockade and peritoneal membrane preservation:the ace of art [J]. J Med Assoc Thai,2011,94(Suppl 4): S175-S183.
47	Kolesnyk I, Struijk DG, Dekker FW, et al. Effects of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease [J]. Neth J Med, 2010, 68(1):15-23.
48	Lewis RV, McDevitt DG. Adverse reactions and interactions with βadrenoceptor blocking drugs [J]. Med Toxicol, 1986, 1 (5):343-361.
49	Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease [ J]. Nephrol Dial Transplant,1988,3(1):66-69.
50	Hendriks PM, Ho-dac-Pannekeet MM, van Gulik TM, et al.Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics[J]. Perit Dial Int,1997,17(2):136-143.
51	Stegmayr BG. Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients [J]. Perit Dial Int,1997,17(6):541-545.
52	Topley N, Petersen MM, Mackenzie R, et al. Human peritoneal mesothelial cell prostaglandin synthesis: induction of cyclooxygenase mRNA by peritoneal macrophage-derived cytokines [J]. Kidney Int,1994,46(3):900-909.
53	Liu H,Peng Y,Liu F, et al. A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells [J]. Cell Biol Int,2007,31(5):508-515.
54	Fabbrini P, Schilte MN, Zareie M, et al. Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis[J]. Nephrol Dial Transplant,2009,24(12):3669-3676.
55	De Vriese AS, Mortier S, Lameire NH. Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis [J].Perit Dial Int,2001,21(Suppl 3): S354-S356.
56	Margetts P. Heparin and the peritoneal membrane [J]. Perit Dial Int,2009,29(1):16-19.
57	Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the DiNAS randomized trial [J]. J Am Soc Nephrol,2002,13(6):1615-1625.
58	Pletinck A, Van Landschoot M, Steppan S, et al. Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion [J]. Nephrol Dial Transplant, 2012,27(2):548-556.
59	Li Y, Xie QH,You HZ,et al. Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients-a randomized crossover trial [J]. Perit Dial Int,2012,32(5):507-515.
60	Haslinger B, Goedde MF, Toet KH, et al. Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering[J]. Kidney Int,2002,62(5):1611-1619.
61	Haslinger B, Kleemann R, Toet KH, et al. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells[J]. Kidney Int,2003,63(6):2065-2074.
62	Duman S, Sen S, Sozmen EY, et al. Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats [J].Int J Artif Organs,2005,28(2):170-176.
63	Patel S, Mason RM, Suzuki J, et al. Inhibitory effect of statins on renal epithelial-to-mesenchymal transition [J]. Am J Nephrol,2006,26(4):381-387.
64	Aarons CB, Cohen PA, Gower A, et al. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity [J]. Annals of surgery, 2007, 245(2):176-184.
65	Zhang Y, Kong J, Deb DK, et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system [J]. J Am Soc Nephrol,2010,21(6):966-973.
66	Klaus G. Renoprotection with vitamin D: specific for diabetic nephropathy [J]? Kidney Int,2008,73(2):141-143.
67	Coronel F, Cigarran S, Gomis A, et al. Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol-a preliminary study [J].Clin Nephrol,2012,78(2):93-99.
68	Nascimento MM, Suliman ME, Silva M, et al. Effect of oral Nacetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study[J]. Perit Dial Int,2010,30(3):336-342.
69	Feldman L, Shani M, Efrati S, et al. N-acetylcysteine improves residual renal function in peritoneal dialysis patients: a pilot study[J]. Perit Dial Int,2011,31(5):545-550.
70	Katsanos GS, Anogeianaki A, Orso C, et al. Mast cells and chemokines[J]. J Biol Regul Homeost Agents,2008,22(3):145-151.
71	Schilte MN, Celie JW, Wee PM, et al. Factors contributing to peritoneal tissue remodeling in peritoneal dialysis [J]. Perit Dial Int,2009,29(6):605-617.
72	Sajwani SH, Bargman JM. Novel ways to preserve the peritoneal membrane [J]. Adv Perit Dial,2012,28:37-41.
73	Nakayama M, Terawaki H. Multidisciplinary clinical strategies for encapsulating peritoneal sclerosis in peritoneal dialysis: Update from Japan [J]. Int J urol,2014, [Epub ahead of print]
74	Krediet RT, Pannekeet MM, Zemel D, et al. Markers of peritoneal membrane status [J]. Perit Dial Int, 1996, 16 (Suppl 1): S42-S49.
75	Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, et al.Longitudinal follow-up of CA125 in peritoneal effluent [J]. Kidney Int,1997,51(3):888-893.
76	Lee TC, Yang JY, Wang HP, et al. Peritoneal thickening is not inevitable in long-term peritoneal dialysis and is associated with peritoneal transport characteristics: a two-centre sonographic study[J]. Nephrol Dial Transplant,2008,23(3):1005-1010.
77	Hoff CM. Ex vivo and in vivo gene transfer to the peritoneal membrane in a rat model [J]. Nephrol Dial Transplant, 2001, 16(3):666-668.
78	Nie J, Dou X, Hao W, et al. Smad7 gene transfer inhibits peritoneal fibrosis [J]. Kidney Int,2007,72(11):1336-1344.

[1]	Jie Xu, Yajun Li, Junwei Han. Comparison of the efficacy of radical laparoscopic total gastrectomy in the treatment of overweight gastric cancer with two approaches [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 19-22.
[2]	Jiehong Gao, Pingping Li, Jing Qi, Yinhai Dai. Study on the relationship between the expression of ETFA gene and clinicopathological parameters and prognosis in breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 64-67.
[3]	Daiqin Li, Peijie Liu. Value of dynamic enhanced magnetic resonance imaging in evaluating the efficacy and prognosis of middle and advanced low rectal cancer after concurrent chemoradiotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 100-103.
[4]	Xiangyu Qu, Yigang Zhang, Haoling Li, Tian Qiu, Yi Tan. Diagnostic and prognostic role of USP24 and its co-expression of tumor metabolic genes in hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 659-662.
[5]	Wen Gu, Shouxin Ling, Haili Tang, Xuemei Gan. Comparison of two different surgical approaches for open radical surgery in patients with papillary thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 687-690.
[6]	Chengwang Fu, Dagang Yang, Rong Wang, Futang Li. Research progress of nutritional and inflammatory markers in resectable pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 704-708.
[7]	Mengjie Liang, Huanhuan Zhu, Xingzhou Wang, Hang Jiang, Shichao Ai, Feng Sun, Peng Song, Meng Wang, Song Liu, Xuefeng Xia, Junfeng Du, Shuang Fu, Xiaofeng Lu, Xiaofei Shen, Wenxian Guan. Analysis of prognosis and postoperative complications of gastric cancer patients undergoing conversion therapy with combined immunotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 619-623.
[8]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[9]	Wei Li, Zijian Song, Yancheng Lai, Rui Zhou, Han Wu, Longxin Deng, Rui Chen. The current state and prospects of artificial intelligence applied to prognosis prediction in prostate cancer patients [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 541-546.
[10]	Zun Chen, Ping Wang, Hua Jin, Meiling Zhou, Qingqing Li, Yonggang Huang. Application of sarcopenia in predicting incisional hernia after colorectal cancer surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(06): 639-644.
[11]	Xiaoling Guan, Wenying Zhou, Hongping Chen. Predictive value of PTAAR for short-term prognosis of patients with hepatitis B virus-related acuteon-chronic liver failure [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 841-845.
[12]	Runjin Zhang, Pan Yang, Yansi Lin, Zunlong Liu, Jianping Liu, Xiaoyan Jin. Epstein-Barr virus-associated cholangiocarcinoma complicated with multiple metastases: a case report and Chinese literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 865-869.
[13]	Xiaopeng Chen, Jiani Wang, Qinghai Lian, Jiumei Yang. Expression of VOPP1 in hepatocellular carcinoma and its relationship with prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 876-882.
[14]	Jiagang Han, Zhenjun Wang. The treatment strategies for obstructive left-sided colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 450-458.
[15]	Zhaorong Guo, Xinguang Wang, Yiqiang Liu, Yingjian He, Lize Wang, Yang Yang, Xing Wang, Wei Cao, Chongshan Gu, Tie Fan, Jinfeng Li, Zhaoqing Fan. Clinicopathologic characteristics and prognostic risk factors of different subtypes of phyllodes tumor of the breast [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(06): 524-532.

Please choose a citation manager

Content to export